Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2507790 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapies.
Ann Hematol
September 2025
Hematology and Transplant Center, University Hospital"San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
Functional high risk multiple myeloma (FHRMM) remains a challenging entity with poor outcomes and limited survival, and there is no international consensus on optimal second-line therapeutic strategies in relapsed/refractory patients. In this multicenter real-world retrospective study, we investigated clinical characteristics and outcomes of a total of 62 FHRMM patients previously treated with a first-line daratumumab-based quadruplet regimen or who relapsed within 12 months after frontline autologous stem cell transplantation (ASCT). In our cohort, the overall response rate was 61%, with 42% of patients achieving a very good partial response (VGPR) or better.
View Article and Find Full Text PDFConsensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group.
Clin Hematol Int
August 2025
University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Anti-CD38 monoclonal antibodies (mAbs), including daratumumab and isatuximab, have become key components of treatment for relapsed/refractory multiple myeloma (RRMM). This expert consensus provides evidence-based guidance on their optimal use, including regimen selection, special considerations for elderly or frail patients, and the treatment of high-risk subgroups. Key topics addressed include the selection of anti-CD38-based regimens, patient stratification by frailty and comorbidities, strategies for managing hematologic toxicities, and considerations for re-treatment.
View Article and Find Full Text PDFInduction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial.
Lancet Haematol
August 2025
Hematology Department, Cancer Center Clínica Universidad de Navarra (CCUN), CIMA, IDISNA, CIBERONC, Pamplona, Spain.
Background: Triplet and quadruplet regimens based on bortezomib, melphalan and prednisone (VMP) and lenalidomide and dexamethasone (Rd) with anti-CD38 antibodies are potential treatments for transplant-ineligible patients with newly diagnosed multiple myeloma. However, the high risk of toxic effects in this population requires frailty-based therapy adaptation. We aimed to compare the response of carfilzomib-based triplet and quadruplet regimens with a VMP-Rd regimen in newly diagnosed transplant-ineligible patients with multiple myeloma, considering patient frailty.
View Article and Find Full Text PDFDaratumumab for High-Risk Smoldering Multiple Myeloma. Reply.
N Engl J Med
August 2025
Mayo Clinic, Rochester, MN.
Daratumumab for High-Risk Smoldering Multiple Myeloma.
N Engl J Med
August 2025
Harvard Medical School, Boston.